Rupatadine relieves allergic rhinitis: a prospective observational study

Area of Science:

• Allergy and Immunology
• Pharmacology
• Clinical Practice Research

Background:

• Allergic rhinitis is a widespread condition in Belgium, significantly affecting patients' quality of life.
• Observational studies offer valuable insights into drug efficacy in daily practice, complementing clinical trials.
• Rupatadine, a second-generation H1-antihistamine, was investigated for its real-world effectiveness.

Purpose of the Study:

• To evaluate the quality of life evolution in allergic rhinitis patients treated with rupatadine in clinical practice.
• To assess the impact of rupatadine on symptom severity and patient-reported outcomes.
• To determine the safety profile of rupatadine in a real-world setting.

Main Methods:

• A prospective, non-interventional, observational, multicenter study.
• Inclusion of 2,838 adult patients diagnosed with moderate to severe allergic rhinitis.
• Assessment using validated scales at baseline and after 6 weeks of rupatadine (10 mg daily) treatment.

Main Results:

• Significant improvements were observed in quality of life (mini-RQLQ, p < 0.001) and symptom severity (T5SS, VAS, ARIA classification, p < 0.001).
• High patient compliance (72.2%) and a low incidence of minor adverse effects were reported.
• Patients reported complete relief (21%) or strong relief (62%) from symptoms.

Conclusions:

• The study confirms the clinical benefit of rupatadine in managing allergic rhinitis in a broad patient population.
• Rupatadine demonstrated effectiveness in clinical practice, even for severe symptoms like nasal congestion.
• Real-world data supports rupatadine's value for improving patient quality of life and symptom control.